SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$3.69 USD
-0.06 (-1.60%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $3.63 -0.06 (-1.63%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.69 USD
-0.06 (-1.60%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $3.63 -0.06 (-1.63%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Zacks News
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
by Zacks Equity Research
SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 17.86% and 10.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 148.39% and 3.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 218.75% and 9.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -13.79% and 0.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -10.71% and 4.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -127.94% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 28.57% and 10.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
SOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 35.29% and 3.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -5.88% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Q3 Earnings Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -1.64% and 2.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?